Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biodel has received a notice of allowance from the European Patent Office for patent claims covering compositions and uses of formulations of insulin for the company's two lead product candidates, VIAject and VIAtab, in the treatment of diabetes.
Subscribe to our email newsletter
After their publication and once they are issued, the patent claims will have a term of 20 years from the international filing date of March 11, 2005.
Solomon Steiner, chairman and CEO of Biodel, said: We are encouraged by this notice of allowance for an important patent that will expand the intellectual property protection for our lead products. We believe this action supports the usefulness and novelty of our ultra-rapid-acting insulin delivery technology and increases the value of our lead products.